CD33 and acute myeloid leukemia: Clinical studies. The first report on the outcome of anti-CD33 CAR-T treatment in a patient with AML dates back to 2015, and was presented by Wang et al. A patient with chronic pancytopenia, ineligible for chemotherapy, was included in this clinical trial.